1-(3,6-二甲基-2-吡嗪基)-2-甲基-1-丙酮 | 145984-66-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(3,6-二甲基-2-吡嗪基)-2-甲基-1-丙酮
• 英文名称: 1-(3,6-Dimethylpyrazin-2-yl)-2-methylpropan-1-one
• CAS: 145984-66-3
• 化学式: C₁₀H₁₄N₂O
• 分子量: 178.23
• InChiKey: OQMKTWPBFFDWJC-UHFFFAOYSA-N

物化性质

• 沸点：
  266.0±35.0 °C(Predicted)
• 密度：
  1.028±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  42.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] OXIMYL MACROCYCLIC DERIVATIVES<br/>[FR] DÉRIVÉS MACROCYCLIQUES D'OXIMYLE
  申请人：ENANTA PHARM INC

  公开号：WO2009073713A1

  公开（公告）日：2009-06-11

  The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: ( i ) which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

  本发明涉及式I化合物，或其药用可接受的盐、酯或前药：(i)抑制丝氨酸蛋白酶活性，尤其是丙型肝炎病毒(HCV) NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且还可用作抗病毒剂。本发明进一步涉及包含前述化合物的药物组合物，用于给患有HCV感染的对象服用。本发明还涉及通过管理包含本发明化合物的药物组合物来治疗主体HCV感染的方法。
• PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS
  申请人：Wagaw Seble

  公开号：US20090156800A1

  公开（公告）日：2009-06-18

  The present invention relates to a process for the preparation of macrocyclic compounds that are useful as hepatitis C virus (HCV) protease inhibitor compounds.
• OXIMYL MACROCYCLIC DERIVATIVES
  申请人：Sun Ying

  公开号：US20090191153A1

  公开（公告）日：2009-07-30

  The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
• US5172706A
  申请人：——

  公开号：US5172706A

  公开（公告）日：1992-12-22
• US5256785A
  申请人：——

  公开号：US5256785A

  公开（公告）日：1993-10-26